Rocket Pharmaceuticals Stock (NASDAQ: RCKT)

Dernières nouvelles pour Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

ROCKET PHARMACEUTICALS INC

Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals Inc

ROCK TECH LINTHIUM INC by Rock Tech Lithium Inc.

Rock Tech Lithium Inc

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) with a Buy and lowers the price target from $50 to $45.

News

Price Target

Analyst Ratings

NGNE

HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $45

WIIM

MVST

Microvast Holdings shares are trading higher after the company reported better-than-expected Q1 sales results.

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

ARWR

Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target

EXOD

Exodus Movement shares are trading lower after the company reported worse-than-expected Q1 sales results.

GigaCloud Technology shares are trading higher after the company reported better-than-expected Q1 financial results.

INDI

Indie Semiconductor shares are trading lower after the company reported worse-than-expected Q1 sales results.

<ul>
<li>ATTRibute-CM, BridgeBio's Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic hypothesis that stabilizing TTR may delay or prevent ATTRv-CM.</li>
<li>ACT-EARLY is a registrational, randomized, double blind, placebo controlled, event driven prevention study that will enroll ~600 asymptomatic carriers of a pathogenic TTR variant. Diagnosis of ATTRv disease will be evaluated as the primary analysis of the study</li>
<li>In the ACT-EARLY study, BridgeBio will partner globally with ATTR amyloidosis treating physicians and patient advocacy organizations with the hope of addressing a serious unmet need and proving that ATTRv can be delayed or prevented.</li>
<li>Acoramidis is approved as Attruby by the U.S. FDA and is approved as BEYONTTRA by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and the UK Medicines and Healthcare Products Regulatory Agency</li>
</ul>

Biotech

Health Care

General

BBIO

BridgeBio Pharma Has Dosed The First Asymptomatic Participant With A Known Pathogenic Transthyretin Variant, Which May Lead To Transthyretin Amyloid Disease In ACT-EARLY Study With Acoramidis

3D Systems shares are trading lower after the company reported worse-than-expected Q1 financial results.

Earnings

Earnings Beats

NERV

Minerva Neurosciences Q1 EPS $(0.50) Beats $(1.07) Estimate

The recent relaxation of tariffs between the U.S. and China has sparked a significant market rally, with tech CEOs and founders reaping substantial benefits.
What Happened: The &#8220;magnificent seven&#8221; stocks, including Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), collectively added nearly $830 billion to their market capitalization, as <a href="https://www.forbes.com/sites/dereksaul/2025/05/12/us-china-tariff-thaw-sparks-stock-rally-making-bezos-musk-and-zuckerberg-more-than-40-billion-richer/">per</a> a Forbes report.
Although Tesla's share price, at $318.38, remains below its all-time high of nearly $490, Elon Musk's net worth rose by $15 billion, reaching $359 billion, as per the Bloomberg Billionaire Index. The rally further solidified his position as the world's richest person.
Amazon&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder, Jeff Bezos, and Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO, Mark Zuckerberg, also saw their net worth rise by $14 billion and $16 billion, respectively. However, both still trail Musk by nearly $130 billion.
SEE ALSO:&nbsp;<a href="https://benzinga.com/trading-ideas/movers/25/05/45368880/xrp-rallies-over-3-tuesday-morning-is-the-coin-heading-toward-3" target="_blank" rel="noreferrer noopener">XRP Rallies Over 3% Tuesday Morning — Is The Coin Heading Toward $3? &#8211; Benzinga</a>
Why It Matters: The U.S. and China agreed to reduce tariff rates, a move that could propel <a href="https://www.benzinga.com/tech/25/05/45357613/china-tariff-de-escalation-biggest-winners-include-tesla-apple-new-tech-highs-back-on-the-table-now-for-2025">technology stocks </a>to new heights, according to Wedbush&#8217;s Dan Ives. The stock of Amazon climbed 8.07%, Meta Platforms rose 7.92%, while Tesla was up 6.75% on Monday. Tesla, led by Musk, surpassed a $1 trillion valuation for the first time since late February.
The 90-day tariff pause between the U.S. and China has resulted in a market rally and positive sentiment. However, experts warn that this is not a <a href="https://www.benzinga.com/government/regulations/25/05/45367206/sp-500-rallies-over-3-on-us-china-90-day-tariff-truce-but-experts-warn-it-doesnt-guarantee-a-complete-resolution-of-the-trade-war">definitive end</a> to the trade war, leaving significant long-term uncertainty. The news triggered an immediate positive market response, with stocks and oil prices rebounding, potentially leading to lower costs for businesses and consumers.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45335756/cathie-wood-stands-firm-on-bold-700000-bitcoin-prediction-for-investors-says-bull-case-in-the-1-5-million-range" target="_blank" rel="noreferrer noopener">Cathie Wood Stands Firm on Bold $700,000 Bitcoin Prediction for Investors, Says ‘Bull Case in the $1.5 Million Range&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Markets

Tech

AAPL

AMZN

NVDA

TSLA

Elon Musk, Jeff Bezos, Mark Zuckerberg Gain Billions As US-China Tariff Truce Boosts Tech Billionaires' Fortunes

POWI

Power Integrations shares are trading lower. The company reported Q1 financial results.

Contracts

V2X Awarded Spot On US Army LTRaC Contract;  LTRaC IDIQ Contract Has A Ceiling Value Of $379M Over An Eight-year Period Of Performance, Including A Five-Year Base And A Three-Year Option Period.

International Game Technology shares are trading lower after the company reported worse-than-expected Q1 financial results and narrowed its FY25 sales guidance.

Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.42) by 61.9 percent. This is a 96.41 percent increase over losses of $(18.94) per share from the same period last year.

Earnings Misses

BCAX

Bicara Therapeutics Q1 EPS $(0.68) Misses $(0.42) Estimate

<a href="https://www.globenewswire.com/Tracker?data=NxiInwnJ0u04ZM_I05yHOCxjuUs5W0PeGG-o8YLNkCpPYn3qbUS4-Z4FAyfvAzje4Xp4vKzxpLcpIcHuddxr2PCwcEvLrRzrEiqNbcFZWf2BwrQalR8p-LMc_d1Kvl05sRd_44NBAv8gs-5axlUferar_sMH-nrT7oKA7jpx-VrXl4Gd1DWqTZ2HGS0MSjtRdpVIYv-WAeRe2D2DqydrvfY0vh1Kzu371HUOi2dySq0=">Caliber</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWD#NASDAQ">CWD</a>), a real estate investor, developer, and manager, today announced the launch of Caliber Hospitality Development, LLC ("CHD"), a joint venture between Caliber and GIA Hospitality, LLC ("GIA"). CHD will serve as the exclusive development platform for Caliber's opportunistic hospitality investments, with a focus on acquiring distressed hotel assets and developing extended stay hotels in high-demand markets.
The joint venture was seeded with an initial $2 million investment from GIA and is supported by Caliber's integrated real estate services, including development, construction, finance, and asset management. CHD will operate independently under the Caliber Hospitality brand.

Caliber Launches Hospitality Venture to Target Distressed Hotels and Extended Stay Markets

ODDITY Tech shares are trading lower after the company announced the sale of 5.5M shares of its Class A ordinary shares by an entitty affiliated with Oran Holtzman

Jefferies analyst Omar Nokta maintains ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) with a Hold and raises the price target from $15 to $16.

Jefferies Maintains Hold on ZIM Integrated Shipping, Raises Price Target to $16

CYTK

Cytokinetics' MAPLE-HCM Phase 3 Trial Comparing Aficamten To The Standard Of Care Beta Blocker Metoprolol For Symptomatic Obstructive Hypertrophic Cardiomyopathy Met Its Primary Endpoint

MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is based on data from the Company's Phase II ChronEx clinical trial in patients with venous leg ulcers (VLUs) evaluating the efficacy and safety of EscharEx&#xAE; compared with collagenase ointment (SANTYL&#xAE;), the only FDA-cleared enzymatic debridement agent commercially available for the treatment of dermal ulcers.
The <a href="https://www.globenewswire.com/Tracker?data=vcrrKBu20hKK41Ce5bD1qXRUThIWpZnX_wY720Hfad0wLiA7Ub_KbJaTTTjNidGLW8d_D5w3ermEL3uFNM6iOsRsyz8VoL24c26uHXW4Xl2fOAQFBQP54IUifi1oAgLgwjfnwxfv2_9lrthX3c4vqyOG5WA4eX-Kbf1Uk1hQ-1yn8YXcGKYUyF83bUYscuz_FI-wxi3lsn8FDOHJf88SCLbLaQDBp1N-81MHio7zfjE=">article</a>, titled "Bromelain-Based Debridement Versus Collagenase Ointment Debridement of Venous Leg Ulcers: Post Hoc Analysis of the ChronEx Trial," appears in the April 2025 edition of Wounds (Index 2025;37(4):166–173) and compares outcomes in a subgroup of patients from the non-surgical standard of care arm treated with SANTYL (n=8) to those treated with EscharEx (n=46).
"These new findings are consistent with my prior experience using EscharEx in clinical trials and SANTYL in clinical practice," said Dr. Cyaandi Dove, DPM, of the University of Texas Health Science Center at San Antonio and co-author of the publication. "Compared to SANTYL, EscharEx achieved faster and more effective debridement and promoted healthier granulation tissue, both key to optimal wound bed preparation. EscharEx's enzymatic formulation targets a wider range of non-viable and necrotic tissue, which may account for the favorable clinical outcomes observed."
Key findings from the post hoc analysis include:
<ul>
<li>Debridement Efficacy:
<ul>
<li>Complete debridement at 2 weeks was achieved in 63% of EscharEx-treated patients, compared to 0% in the SANTYL group (p = 0.001).</li>
<li>Median time to debridement was 9 days for EscharEx vs. not achieved for SANTYL (p = 0.023).</li>
</ul>
</li>
<li>Wound Bed Preparation (WBP):
<ul>
<li>WBP—defined as complete debridement and complete granulation—was achieved by 50% of EscharEx patients in 2 weeks vs. 0% with SANTYL (p = 0.015).</li>
<li>Over the entire study period (12 weeks), 78% of EscharEx patients achieved WBP vs. 38% with SANTYL (p = 0.03).</li>
<li>Median time to WBP: 11 days for EscharEx; not achieved for SANTYL (p = 0.014).</li>
</ul>
</li>
<li>Wound Closure:
<ul>
<li>Closure was achieved in 33% of EscharEx patients vs. 25% with SANTYL (not statistically significant).</li>
<li>Among those who closed, the mean time to closure was 48 days for EscharEx vs. 76 days with SANTYL (p = 0.05).</li>
</ul>
</li>
<li>Safety and Tolerability:
<ul>
<li>Adverse event rates and applicational pain were similar between groups.</li>
<li>Deep wound infection, assessed using recognized clinical criteria, occurred in 11% of EscharEx patients compared to 38% in the SANTYL group.</li>
</ul>
</li>
</ul>

MDWD

MediWound's EscharEx Outperforms SANTYL in Healing Venous Leg Ulcers, Study Shows

Hertz Global Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results.

Press Releases

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Comments

Rocket Pharmaceuticals

Actualités

Dernières nouvelles pour Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL